Connect your agent to akta.pro and build company lists like this across sectors and geos.
Private US-headquartered biotech startups at Series B or later, ranked by total capital raised. The shortlist spans oncology, gene and cell therapy, antibody engineering, precision medicine, RNA therapeutics and AI-assisted drug discovery. Data compiled .
| Company | Category | Funding | Products & Services | Expansion Signal | Management |
|---|---|---|---|---|---|
| Rakuten Medical 🇺🇸 San Diego Founded 2010 101-250 employees | Oncology Therapeutics | Funding $847.0M Last raised Undisclosed Apr 2026 · Series Unknown | Develops light-activated cancer therapies that pair antibody-dye conjugates with a laser system to destroy tumor cells, with its lead candidate marketed in Japan. ASP-1929 BioBlade Laser System RM-1995 RM-0256 | Ecosystem Buildout Announced plans to bring its light-activated cancer therapy to the US market. | Minami Maeda President and incoming CEO (effective July 1, 2026) Hiroshi \"Mickey\" Mikitani Executive Chairman of the Board (effective July 1, 2026) Abhijit Bhatia Chief Operating Officer (COO) Carlos Garcia Chief Technology Officer (CTO) and U.S. Divisional Officer |
| Enveda Biosciences 🇺🇸 Boulder Founded 2019 251-500 employees | Drug Discovery & Development (Natural Product-Derived Pharmaceuticals) | Funding $840.9M Last raised $311.0M Sep 2026 · Series E | Discovers small-molecule drug candidates from natural products, primarily plants, using an AI platform that combines mass spectrometry with proprietary data to find new therapies. ENV-294 ENV-308 ENV-6946 | Ecosystem Buildout Partnered with an AI developer to speed drug development, cutting review time for its drug records by 89%. | Viswa Colluru, PhD Founder & CEO August Allen Chief Technology Officer Daniel Wee, PhD Chief eXecution Officer Hannah Gordon, PhD Chief Scientific Officer |
| Tessera Therapeutics 🇺🇸 Somerville Founded 2018 101-250 employees | Gene Therapy / Genetic Medicine | Funding $773.1M Last raised Undisclosed Mar 2026 · Grant | Develops in vivo gene editing therapies using a gene writing platform that makes precise genome changes, including single-base edits and insertions, delivered by lipid nanoparticles. Gene Writing™ Lipid Nanoparticle (LNP) Delivery Platform TSRA-196 In Vivo Sickle Cell Disease (SCD) Program | New Product Line Received FDA Fast Track and Orphan Drug designations for its lead genetic medicine program. | Michael Severino Chief Executive Officer, Board Director Jacob Rubens Co-Founder Noubar Afeyan Founder and CEO of Flagship Pioneering (Tessera Founding Team member) Hari Pujar Chief Operating Officer |
| NewLimit 🇺🇸 South San Francisco Founded 2022 11-50 employees | Epigenetic Therapeutics | Funding $682.2M Last raised $435.0M Jun 2026 · Series C | Develops epigenetic reprogramming medicines that restore youthful function to aged cells using transcription factor payloads delivered by lipid nanoparticle mRNA, starting with liver disease programs. Metabolism Program Immunology Program Vascular Program | — | Jacob Kimmel Co-founder & CEO Brian Armstrong Co-founder & Board Director Blake Byers Co-founder |
| Chai Discovery 🇺🇸 San Francisco Founded 2024 11-50 employees | AI Drug Discovery | Funding $631.0M Last raised $400.0M Jul 2026 · Series C | Builds generative AI foundation models that predict and reprogram molecular interactions, designing novel antibodies, nanobodies and other biologics for drug discovery partners. Chai-1 Chai-2 Chai-2 mAb Chai-3 | Ecosystem Buildout Expanded its collaboration with a large pharmaceutical company after successful wet-lab validation of its AI models. | Joshua Meier Co-founder and CEO Jack Dent Co-founder and President Matt McPartlon Co-founder Jacques Boitreaud Co-founder |
| Colossal Biosciences 🇺🇸 Austin Founded 2021 251-500 employees | Biotechnology | Funding $628.1M Last raised $60.0M Feb 2026 · Series C | Applies CRISPR gene editing, ancient DNA assembly, stem cell reprogramming and reproductive biology to pursue functional de-extinction of lost species. Woolly Mammoth De-Extinction Program Thylacine (Tasmanian Tiger) De-Extinction Program Dodo De-Extinction Program Dire Wolf De-Extinction Program | New Product Line Deployed a new AI platform to support its dodo de-extinction effort. | Ben Lamm Co-founder & CEO George Church, Ph.D. Founder & Lead Geneticist Brian Beard Co-Founder & Chief Legal Officer Kent Wakeford Co-Founder & COO |
| Kallyope 🇺🇸 New York Founded 2015 51-100 employees | Biopharmaceutical Therapeutics | Funding $581.2M Last raised $94.0M Oct 2026 · Series Unknown | Discovers and develops therapeutics targeting the gut-brain axis, led by an oral TRPM8 antagonist in Phase 3 development for acute migraine. Elismetrep K-554 Klarity™ Platform Novo Nordisk Obesity Ligand Program | M&A Signal Sold three early-stage obesity programs to a large pharmaceutical company and refocused on late-stage migraine trials. | Jay Galeota President & Chief Executive Officer Thomas Maniatis Co-Founder Charles Zuker Co-Founder Richard Axel Co-Founder |
| LifeMine Therapeutics 🇺🇸 Cambridge Founded 2017 51-100 employees | Drug Discovery & Development | Funding $563.0M Last raised $188.0M Aug 2026 · Series E | Mines fungal genomes with AI, machine learning and synthetic biology to discover genetically encoded precision medicines, with a clinical-stage candidate for organ transplantation. Avatar-Rx Platform LIFE-001 GlaxoSmithKline (GSK) Drug Discovery and Development Alliance | Ecosystem Buildout Formed a clinical advisory board of organ transplantation experts to advance its transplant drug candidate. | Gregory Verdine, Ph.D. Co-Founder, President and CEO Richard Klausner, M.D. Co-Founder and Chairman of the Board WeiQing Zhou, MBA Co-Founder and COO Jennifer Jarrett, MBA Board Member; CEO, Damora Therapeutics |
| Orca Bio 🇺🇸 Menlo Park Founded 2016 251-500 employees | Cell Therapy / Biologics | Funding $542.0M Last raised $250.0M Jan 2026 · Series F | Develops high-precision allogeneic T-cell immunotherapies for blood cancers and autoimmune diseases, manufactured on a proprietary single-cell platform that creates defined cell compositions. Orca-T Orca-Q OrCAR-T | New Product Line Won FDA approval for Orca-T (Tregzi), the first regulatory T-cell therapy cleared for adults undergoing matched-donor stem cell transplant. | Nate Fernhoff, PhD Co-founder and Chief Executive Officer Jeroen Bekaert, PhD Co-founder and President Bijan Nejadnik, MD Chief Medical Officer J. Scott McClellan, MD, PhD Chief Development Officer |
| Abcuro 🇺🇸 Newton Founded 2020 11-50 employees | Biopharmaceuticals | Funding $520.2M Last raised $66.0M Aug 2026 · Series D | Develops first-in-class monoclonal antibodies targeting KLRG1 to deplete highly cytotoxic T cells implicated in autoimmune disease and cancer, with a lead candidate in late-stage development. Ulviprubart ABC015 | — | Alex Martin Chief Executive Officer Steven A. Greenberg, M.D. Co-founder and Chief Scientific Advisor H. Jeffrey Wilkins, M.D. Chief Medical Officer George Eldridge Chief Financial Officer |
| Star Therapeutics 🇺🇸 South San Francisco Founded 2018 11-50 employees | Biopharmaceuticals | Funding $515.0M Last raised $200.0M Oct 2026 · Private Equity Round | Discovers and develops first-in-class antibody therapeutics for rare diseases, led by a Phase 3 monoclonal antibody that targets Protein S in von Willebrand disease. VGA039 ELA026 ELA822 | M&A Signal Incyte acquired its Vega Therapeutics subsidiary, which holds VGA039, for $1.25B upfront plus up to $750M in milestones. | Adam Rosenthal, PhD CEO and Founder Sandip Panicker, PhD CSO and Co-Founder Gary Patou, MD CMO Scott Robertson, MBA CBO and CFO |
| Encoded Therapeutics 🇺🇸 South San Francisco Founded 2014 101-250 employees | Gene therapy for neurological disorders | Funding $514.1M Last raised $275.0M Sep 2026 · Series F | Develops one-time AAV-based precision gene therapies that target the underlying genetic cause of severe neurological disorders, with programs in Dravet and Angelman syndromes. ETX101 ETX301 Angelman Syndrome Program Alzheimer's Disease / Tauopathies Program | Ecosystem Buildout Planned a facility expansion in North Carolina after its latest financing. | Kartik Ramamoorthi, Ph.D. Co-founder, Chief Executive Officer & Board Member Stephanie Tagliatela Co-founder, Chief Scientific Officer & Board Member Sean P. Nolan Board Chairman Salvador Rico, M.D., Ph.D. Chief Medical Officer |
| Vedanta Biosciences 🇺🇸 Cambridge Founded 2013 51-100 employees | Microbiome Therapeutics | Funding $477.0M Last raised $40.0M Aug 2026 · Venture Financing | Develops oral live biotherapeutic products made of rationally designed defined bacterial consortia to treat gastrointestinal diseases, led by an eight-strain commensal consortium. VE303 VE202 VE707 Product Engine | New Product Line Cleared a prespecified interim analysis of its pivotal Phase 3 trial, which will continue as planned. | Bernat Olle, Ph.D. Co-founder, Chief Executive Officer, and Board of Directors Alexander Rudensky Scientific Co-founder Dan Littman Scientific Co-founder Ruslan Medzhitov Co-founder & Chair of Scientific Advisory Board |
| EGenesis 🇺🇸 Cambridge Founded 2015 101-250 employees | Xenotransplantation Therapeutics | Funding $470.0M Last raised $14.0M Aug 2026 · Convertible Note | Engineers genetically modified pig organs, including kidneys, livers and hearts, using multiplex CRISPR editing that inactivates retroviruses and humanizes tissue for transplantation into patients. EGEN-2784 EGEN-5784 ELC EGEN-4467 | Funding Signal A pharmaceutical partner raised its strategic investment in the xenotransplantation developer. | Michael Curtis, Ph.D. President & Chief Executive Officer Jay Barth, M.D. Chief Medical Officer Jennifer Bergheiser Chief Commercial Officer Glenn S. Vraniak Chief Financial Officer |
| Angitia Biopharmaceuticals 🇺🇸 Westlake Village Founded 2018 51-100 employees | Musculoskeletal Biopharmaceuticals | Funding $406.0M Last raised $130.0M Feb 2026 · Series D | Develops a pipeline of three bispecific antibody drug candidates for serious musculoskeletal diseases, with clinical-stage biologics programs advancing through development. AGA2118 AGA2115 AGA111 | — | Hua Zhu Ke Founder and CEO |
| Soufflé Therapeutics 🇺🇸 Boston Founded 2021 51-100 employees | RNA-based Genetic Medicines | Funding $335.0M Last raised $135.0M Oct 2026 · Series B | Engineers cell-specific ligands that carry small interfering RNA drugs across cell membranes into target cells such as cardiomyocytes and skeletal muscle cells. | — | Amir Nashat Chief Executive Officer Susan Langer Chief Business Officer Vadim Dudkin Founding Chief Technology Officer Victor Kotelianski Founder |
| Wugen 🇺🇸 St Louis Founded 2018 11-50 employees | Cell Therapy / Oncology Biotechnology | Funding $322.0M Last raised $35.0M Jul 2026 · Series C | Develops allogeneic off-the-shelf cell therapies for cancer, led by a CD7-targeted CAR-T therapy for relapsed or refractory T-cell malignancies and a natural killer cell program. Soficabtagene Geleucel WU-NK-101 | New Product Line Won FDA Breakthrough Therapy Designation for sofi-cel, its off-the-shelf CD7-targeted CAR-T therapy for T-cell leukemia and lymphoma. | Kumar Srinivasan, Ph.D., M.B.A. President and Chief Executive Officer Matt Cooper, Ph.D. Co-founder and Chief Scientific Officer Cherry Thomas, M.D. Chief Medical Officer Jim Faulkner, Ph.D. Chief Technology Officer |
| CREATE Medicines 🇺🇸 Cambridge Founded 2019 11-50 employees | In Vivo CAR Immunotherapy | Funding $311.3M Last raised $122.0M May 2026 · Series B | Develops in vivo chimeric antigen receptor therapies that program immune cells directly inside the body using a proprietary mRNA lipid nanoparticle platform in clinical-stage programs. MT-302 MT-303 MT-304 CRT-401 | Ecosystem Buildout Expanded its in vivo CAR pipeline and lipid nanoparticle technology suite through a new strategic collaboration. | Daniel Getts Chief Executive Officer, Cofounder, Board Director Brett Kaplan Chief Financial Officer and Chief Business Officer Matthew Maurer Chief Medical Officer Robert Hofmeister Chief Scientific Officer |
| Genesis Molecular AI 🇺🇸 Burlingame Founded 2019 101-250 employees | AI Drug Discovery | Funding $296.1M Last raised $40.0M May 2026 · Corporate Funded | Builds an AI operating system for drug discovery that integrates proprietary foundation models, autonomous agents and exploratory tooling used by chemists across the design-make-test cycle. GEMS Pearl Foundation Model DeCAF-Pearl Pearl System | Ecosystem Buildout Expanded its collaboration with a pharmaceutical partner to discover molecules against at least five new targets. | Evan Feinberg CEO and Co-founder Sergey Edunov CTO Will McCarthy COO |
| Flare Therapeutics 🇺🇸 Cambridge Founded 2021 51-100 employees | Precision Oncology Therapeutics | Funding $290.0M Last raised $85.0M Jun 2026 · Series C | Develops precision oncology small-molecule drugs that target transcription factors using a proprietary switch-site discovery platform, led by an oral PPARG inhibitor in clinical development. FX-909 FX-111 | — | Douglas Manion, M.D., FRCP (C) Chief Executive Officer Robert Sims, Ph.D. Chief Scientific Officer and Co-founder Stephen L. Eck, M.D., Ph.D. Chief Medical Officer Daphne Karydas, M.B.A. President and Chief Financial Officer |
| Life Biosciences 🇺🇸 Boston Founded 2017 11-50 employees | Gene Therapy | Funding $288.7M Last raised $80.0M Apr 2026 · Series D | Develops gene therapies built on partial epigenetic reprogramming to treat age-related diseases, led by an AAV-delivered OSK candidate now in clinical trials. ER-100 ER-300 Chaperone-Mediated Autophagy (CMA) Platform Program | New Product Line Reported early promise for its eye gene therapy in a small glaucoma trial. | Jerry McLaughlin Director & Chief Executive Officer David Sinclair, PhD, AO Chairman & Co-Founder Tristan Edwards Co-Founder Michael Ringel, PhD Chief Operating Officer |
| Triveni Bio 🇺🇸 Watertown Founded 2023 11-50 employees | Antibody Therapeutics | Funding $272.0M Last raised $65.0M Jun 2026 · Series C | Develops antibody-based therapeutics for immunological and inflammatory diseases, including a Phase 2 dual KLK5/7 inhibitor for atopic dermatitis and a bispecific antibody in Phase 1. TRIV-509 TRIV-573 TRIV-920 | — | Vishal Patel, PhD Chief Executive Officer Leonard Zon Founder Tillman Gerngross Founder Bhaskar Srivastava, MD, PhD Chief Medical Officer |
| Atavistik Bio 🇺🇸 Cambridge Founded 2021 11-50 employees | Precision Allosteric Therapeutics | Funding $260.0M Last raised $40.0M Mar 2026 · Series B | Develops precision allosteric small-molecule therapeutics for metabolic diseases and cancer, led by an oral AKT1-selective inhibitor in Phase 1/2 for hereditary hemorrhagic telangiectasia. ATV-1601 JAK2 V617F Mutant-Selective Inhibitor Program AMPS (Atavistik Metabolite-Protein Screening) Platform | Ecosystem Buildout Entered a drug-discovery research collaboration with a global pharmaceutical company. | Bryan E. Stuart Chief Executive Officer Jared Rutter, PhD Co-founder and Scientific Advisory Board Co-Chair Ralph J. DeBerardinis, MD, PhD Co-founder and Scientific Advisory Board Co-Chair Marion Dorsch, PhD President and Chief Scientific Officer |
| Hexagon Bio 🇺🇸 Menlo Park Founded 2017 51-100 employees | Oncology Biopharmaceuticals (ADC Development) | Funding $255.6M Last raised $62.0M Oct 2026 · Series C | Discovers small-molecule payloads for antibody-drug conjugates to overcome cancer treatment resistance, mining cytotoxic natural products from microbial genomes with genomics, machine learning and synthetic biology. HEX-360 ADC 2 ADC 3 Dual Combo 1 | — | Maureen Hillenmeyer, PhD Chief Executive Officer and Co-Founder Colin Harvey, PhD Vice President, Synthetic Biology and Head of Platform; Co-Founder Brian Naughton, PhD Head of Data; Co-Founder Yi Tang, PhD Co-Founder |
| Ray Therapeutics 🇺🇸 Berkeley Founded 2021 11-50 employees | Ophthalmic Gene Therapy Biopharmaceuticals | Funding $255.0M Last raised $8.0M Sep 2026 · Grant | Develops optogenetic gene therapies that use light-sensitive proteins delivered by AAV to reprogram surviving retinal neurons and restore visual signal transmission to the brain. RTx-015 RTx-021 Ray Therapeutics Optogenetics Platform | — | Paul Bresge Co-Founder and Chief Executive Officer Chris Whitmore, CPA Chief Financial Officer Peter Francis, MD, PhD Chief Medical & Scientific Officer Jenny Holt Chief Development Officer |
A company qualifies when it develops therapeutics, biologics or genetic and cell-based medicines, or the platform technology used to discover them, and holds its own pipeline or drug-discovery programs. This covers small molecules, antibodies, gene and cell therapies, RNA medicines and AI-driven discovery companies that advance their own candidates.
The list separates therapeutic developers from the tools, diagnostics, clinical-research services and discovery-services providers that share the same akta.pro industry code. Across the 25 companies the largest segment by capital is small molecules, with $2.23B raised by five companies, followed by gene therapy and antibodies.
The 25 companies have raised $11.88B in total, and the top three account for $2.46B, or 20.7% of that amount.
Out of scope: public companies (including one that completed an IPO on 26 October 2026), life science tools, diagnostics, clinical-research and discovery-services providers, companies headquartered outside the US, and any company whose latest round predates 2026 or is below Series B.
Companies are tagged against standard industry codes and against akta.pro's internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) 325414 Biological Product (except Diagnostic) Manufacturing 5417 Scientific Research and Development Services SIC 2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) 2834 PHARMACEUTICAL PREPARATIONS 8731 SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH Internal taxonomy HLAA Biotechnology & BiologicsIndustry codes are provided for cross-referencing against public filings and procurement records. akta.pro classification is independent of them, so a company may carry an internal segment without a matching NAICS or SIC registration.